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the use of this
combination regimen.
This phase 2 study evaluated isatuximab as monotherapy or combined with dexametha-
sone in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to
an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) or had received ‡3 prior
lines of therapy incorporating an IMiD and PI. Patients received isatuximab either as
monotherapy (20 mg/kg on days 1, 8, 15, and 22 [once weekly] of cycle 1 followed by
20 mg/kg on days 1 and 15 of subsequent cycles; Isa group) or in combination with
dexamethasone (40 mg/d [20 mg/d in patients aged ‡75 years] once weekly; Isa-dex
group). Treated patients (N5 164) had received amedian of 4 (range, 2-10) prior treatment
lines. Patients received a median of 5 (1-24) and 7 (1-22) treatment cycles; at data cutoff,
13 (11.9%) of 109 and 15 (27.3%) of 55 patients remained on treatment in the Isa and Isa-dex
arms, respectively. Overall response rate (primary efficacy end point) was 23.9% in the Isa
arm and 43.6% in the Isa-dex arm (odds ratio, 0.405; 95% confidence interval, 0.192-0.859;
P 5 .008). Median progression-free survival and overall survival were 4.9 and 18.9 months
for Isa, and 10.2 and 17.3 months for Isa-dex. Infusion reactions (mostly grade 1/2) and
hematologic abnormalities were the most common adverse events. There was a similar
incidence of grade 3 or higher infections in both groups (22.0% and 21.8%). In conclusion, addition of dexamethasone to
isatuximab increased response rates and survival outcomes with no detrimental effect on safety. This trial was reg-
istered at www.clinicaltrials.gov as #NCT01084252. (Blood. 2021;137(9):1154-1165)
Introduction
CD38 is a cell surface receptor, ectoenzyme, and an attractive
target for the treatment of multiple myeloma (MM) as it is reliably
expressed on malignant plasma cells.1,2 Isatuximab is a CD38-
targeting immunoglobulin G1 monoclonal antibody approved in
the United States and the European Union in combination with
pomalidomide and dexamethasone for the treatment of relapsed/
refractory MM (RRMM).3,4 Isatuximab eliminates MM cells via
antibody-dependent cellular cytotoxicity, antibody-dependent
cellular phagocytosis, complement-dependent cytotoxicity, and
direct apoptosis; it may also affect the tumor immunosuppressive
environment via inhibition of CD38 adenosinergic activity.5-7
Dexamethasone is a commonly used backbone treatment of
multiagent regimens.8-10 Steroids are also used for infusion re-
action (IR) prophylaxis with monoclonal antibodies.11,12 In ad-
dition to a direct antitumor effect, steroids have immunomodulatory
properties,13 the effects of which when given with immunomodu-
latory monoclonal antibodies have not been characterized.
In the dose-finding stage 1 of an international phase 1/2 study to
evaluate the safety and efficacy of single-agent isatuximab in
patients with RRMM, patients received doses ranging from 3 to
20 mg/kg.14 In patients with a median of 5 prior lines of therapy,
isatuximab was generally well tolerated and active at doses
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$10 mg/kg, with an overall response rate (ORR; primary end
point) of 20% to 29%. There was no clear dose–response re-
lationship observed between 10 and 20 mg/kg, and pharmaco-
kinetic (PK) analysis supported a choice of 20mg/kg once weekly/
once every 2 weeks for stage 2 of the study. The antitumor activity
of this single-agent isatuximab dose in patients with RRMM was
confirmed in the Japanese phase 1/2 ISLANDS (Isatuximab Single
Agent Study in Japanese Relapsed AND Refractory Multiple
Myeloma Patients; ORR, 36.4% [12 of 33]) study.15
We report results from stage 2 of the international phase 1/2
study, evaluating the efficacy and safety of isatuximab 20 mg/kg




The dose-finding stage of this phase 1/2 randomized, in-
ternational, multicenter study has been published previously
(clinicaltrials.gov identifier #NCT01084252).14 The objective of
stage 2 of the study was to evaluate the activity of isatuximab at
the selected dose/schedule from the dose-finding stage, as
monotherapy and combined with dexamethasone in patients
with RRMM.
The study was conducted according to the principles of the
Declaration of Helsinki and the International Council for Har-
monisation of Technical Requirements for Pharmaceuticals for
Human Use Good Clinical Practice. The protocol was approved
by the appropriate institutional review boards/ethics commit-
tees. All patients provided written informed consent.
Study population
Eligible patients had MM refractory to both an immunomodu-
latory agent (IMiD) and a proteasome inhibitor (PI), or had been
treated with$3 prior lines of therapy including an IMiD and a PI.
Patients had to have received an alkylating agent, achieved at
least a minimal response to a prior line of therapy, and could
have received prior stem cell transplant. Patients were aged$18
years, with an Eastern Cooperative Oncology Group perfor-
mance status #2 or Karnofsky performance status $60, serum
creatinine level #2 times the upper limit of normal and/or es-
timated glomerular filtration rate (per Modification of Diet in
Renal Disease equation) $15 mL/min/1.73 m2, and measurable
disease. No other anticancer medications were permitted for the
study duration except palliative radiotherapy.
Treatment
Patients were randomized in a 2:1 ratio using an interactive
voice/Web response system to receive IV isatuximab 20 mg/kg
once weekly (days 1, 8, 15, and 22) for 4 infusions followed by
20 mg/kg every 2 weeks (days 1 and 15), either as monotherapy
(Isa arm) or in combination with dexamethasone (Isa-dex arm).
Dexamethasone was administered IV or orally at a dose of
40 mg/d (or 20 mg/d for patients aged $75 years) on days 1, 8,
15, and 22 of each 28-day cycle.
The isatuximab infusion rate was initially 175 mg/h, increasing to
a maximum of 400 mg/h in the absence of IRs. All patients
received IR prophylaxis 15 to 30 minutes before isatuximab
infusion consisting of diphenhydramine 25 to 50 mg IV (or
equivalent), methylprednisolone 100 mg IV (or equivalent; Isa
arm only), ranitidine 50 mg IV (or equivalents for each), and
acetaminophen (paracetamol) 650 to 1000 mg taken orally.
Dexamethasone was administered instead of methylpredniso-
lone in the Isa-dex arm as pre-medication and as part of the
combination treatment.
No isatuximab dose reductions were permitted. No more than 2
dose reductions of dexamethasone were allowed (for toxicity);
after a decrease, re-escalation to the previous dose level was not
permitted. Cycle delay up to 14 days, and dose delay up to
3 days within a cycle, was allowed. In cycle 1 only, if dose delay
beyond 3 days was required, the dose could be omitted, and the
cycle extended from 28 to 35 days to allow for 4 infusions of
isatuximab to be given. Nomore than 2 consecutive omissions of
isatuximab infusion were permitted.
In the Isa-dex arm, if one study drug was prematurely dis-
continued, patients could continue receiving the other. Patients
continued treatment until disease progression, an unacceptable
adverse event (AE) occurred, or any other reason for discontinuation.
Outcomes
The primary efficacy end point was ORR, defined as the pro-
portion of patients with a partial response (PR) or better,
assessed by the Independent Adjudication Committee (IAC)
using International Myeloma Working Group criteria.16 Efficacy
was also assessed by investigators using local laboratory results.
Disease assessment was made on day 1 of cycle 2, and every 4
weeks, whenever disease progression was suspected, to confirm
PR or complete response (CR), and at the end-of-treatment visit.
Secondary efficacy end points included duration of response,
clinical benefit response rate (minimal response or better),
progression-free survival (PFS), and overall survival (OS).
Patients with documented disease progression were followed up
60 days after the last dose of study treatment (isatuximab or
dexamethasone, whichever was stopped last) and then every
3 months until death or the cutoff date. Patients without disease
progression at the end of treatment and who had not started
another anticancer therapy were followed up for efficacy and
safety every 4 weeks until disease progression, death, or the
cutoff date.
Safety was evaluated based on physical examination, laboratory
test results, and reports of AEs graded per National Cancer
Institute Common Terminology Criteria for Adverse Events
version 4.03. Antidrug antibodies were assessed on days 1 and
15 of the first cycle, at the first dose of each subsequent cycle,
the end of treatment, and 60 days’ posttreatment.
Population PK analysis by using nonlinear mixed effects mod-
eling was conducted based on isatuximab concentrations in
blood samples collected before each isatuximab dose. Explor-
atory analyses investigated change in paraprotein, analysis of Fc
g receptor (FCGR3A) polymorphism from baseline blood sam-
ples, the relationship between adaptive immune responses (T-cell
receptor [TCR] clonality), and immune phenotyping with param-
eters of clinical response. TCR DNA sequencing for repertoire
profiling was conducted on whole blood samples collected
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before isatuximab administration on day 1 of cycles 1, 3, and 5
to quantify expansion of individual T-cell clones.
Specific cell protein marker quantification for immunopheno-
typing was performed on whole blood samples collected before
isatuximab administration on day 1 of cycles 1 and 3. Blood
samples were lysed with fluorescence-activated cell sorter lysing
solution and stained with 6 multi-fluorochrome (8-color) anti-
body panels and a CD38-fluorescein isothiocyanate multi-
epitope antibody that binds to epitopes distinct from the
epitope bound by isatuximab (CYT-38F2, Cytognos S.L.). The
analysis was performed by using fluorescence-activated cell
sorter Navios or LSRII flow cytometers, and data were analyzed
by using Infinicyt flow cytometry software (Cytognos S.L.).
Immune cell subpopulations were represented as a percentage
of total nucleated cells unless indicated otherwise.
DNA from patient blood samples was assessed by using an
immunoSEQ Assay (Adaptive Biotechnologies) for TCR re-
arrangements. Analysis was performed by using prequalified
multiplex polymerase chain reaction assays (TR2015CRO-V-019)
that included primers targeting the variable (V) and joining (J)
gene families. Priming pairs of V and J were used to amplify
somatically recombined TCRs. Each initially amplified region was
amplified a second time with forward and reverse primers
containing a universal sequence and an adaptor sequence
needed for DNA sequencing by Illumina.17
The T-cell clonality metric quantitates the extent of clonal ex-
pansion by measuring the shape of clone frequency distribution
after deep sequencing of the TCRb gene on genomic DNA
extracted from patient blood samples. Values range from 0 to 1;
values approaching 1 indicate a nearly monoclonal population.
Statistical analyses
Efficacy and safety analyses were performed on the safety
population comprising patients who received $1 full or partial
dose of isatuximab for the Isa arm and patients who received
dexamethasone in addition to isatuximab for the Isa-dex arm.
ORR difference between arms was tested for significance by
using Fisher’s exact test with a one-sided significance level of
0.025. Estimates of survival (PFS and OS) were calculated by
using the Kaplan-Meier method and log-rank test at a one-sided
significance level of 0.025. FCGR3A polymorphism analysis was
summarized with descriptive statistics. Immunophenotyping
analyses were summarized with descriptive statistics and pre-
sented according to treatment arm and ORR; statistical tests were
not performed due to a limited sample size for some subgroups.
P values for the analysis of median changes from baseline of TCR
clonality were derived by using a Wilcoxon signed rank test. The




The final analysis cutoff date for stage 2 of this phase 2 study was
January 21, 2019, twelve months after the last enrolled patient
completed the first cycle of treatment. Of the 165 patients
randomized to treatment, 109 in the Isa arm and 55 in the Isa-dex
arm were treated and included in the safety population. At data
cutoff, 13 (11.9%) of 109 patients in the Isa arm and 15 (27.3%) of
55 patients in the Isa-dex arm remained on treatment. The most
common reason for treatment discontinuation was disease
progression (Isa, 64.2%; Isa-dex, 60.0%) (Figure 1).
Demographic data and patient medical history are presented in
Table 1. There were no notable imbalances in patient charac-
teristics. In the Isa and Isa-dex arms, 21% and 22% of patients,
respectively, had high-risk cytogenetics, defined as del(17p), t(4:
14), and/or t(14;16) according to central or local (if central was
not available) laboratory data. Four patients in each arm with a
creatinine clearance level of 15 to 30 mL/min/1.73 m2 were
included.
Patients in both arms had a median of 4 (range, 2-10) prior lines
of therapy. In the Isa and Isa-dex arms, 69.7% and 76.4% of
patients, respectively, were refractory to both an IMiD and PI
(double refractory), and .89% of patients in each arm were
refractory to their last regimen.
Patients received amedian (range) of 5 (1-24) and 7 (1-22) cycles,
and the duration of exposure to treatment was 18.9 (1.0-97.0)
and 30.0 (1.0-91.9) weeks in the Isa and Isa-dex arms, re-
spectively. The median relative dose intensity was.97% in both
treatment arms.
The duration of the first infusion of isatuximab 20 mg/kg was a
median of 5.0 hours in the Isa arm and 4.8 hours in the Isa-dex
arm. This was reduced to a median of 4.5 hours in both arms for
subsequent infusions.
Efficacy
Best responses per IAC assessment are given in Figure 2. The
ORR was 23.9% (26 of 109 patients; 95% confidence interval [CI],
0.162-0.330) in the Isa arm and 43.6% (24 of 55 patients; 95% CI,
0.303-0.577) in the Isa-dex arm (odds ratio [OR], 0.405; 95% CI,
0.192-0.859; P 5 .008). Responses were either PRs (Isa, 14.7%;
Isa-dex, 23.6%) or very good partial responses [VGPRs; Isa, 9.2%;
Isa-dex, 20.0%). The overall clinical benefit response rate was
43.1% (47 of 109 patients) and 54.5% (30 of 55 patients) with Isa
and Isa-dex, respectively.
Per investigator assessment, the ORR was 27.5% (30 of 109
patients) with Isa and 45.5% (25 of 55 patients) with Isa-dex (OR,
0.456; 95% CI, 0.220-0.951; P , .02). These findings are in
accordance with the IAC assessment of disease response.
When disease responses in the Isa and Isa-dex arms were an-
alyzed according to a prespecified subgroup, the ORR was
23.7% (18 of 76) and 38.1% (16 of 42) in those who were double
refractory to IMiD and PI; 22.8% (23 of 101) and 41.2% (21 of 51)
for those with $3 prior lines of therapy, including $1 PI and $1
IMiD; and 19.6% (10 of 51) and 39.3% (11 of 28) for patients with
$4 prior lines of therapy whose disease was refractory to$2 PIs
and $2 IMiDs. Based on cytogenetics, the ORR was 4.3% (1 of
23) and 16.7% (2 of 12) for high-risk patients, and 31.6% (18 of
57) and 58.3% (14 of 24) for standard-risk patients in the Isa and
Isa-dex arms, respectively.
When responses were examined according to cumulative
dexamethasone exposure, ORR in patients with a total cumu-
lative exposure greater than the median (840 mg) for all patients
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was 70.4% (19 of 27 patients). In patients with a cumulative
dexamethasone exposure lower than the median for all patients,
ORR was 17.9% (5 of 28 patients).
Median (range) time to first response was 1.0 (1-9) months and
1.0 (1-11) months in the Isa and Isa-dex arms, respectively
(supplemental Figure 1, available on the Blood Web site). Me-
dian (range) time to best response was 2.0 (2-10) and 2.1 (2-12)
months in the Isa and Isa-dex arms (supplemental Figure 1).
Median (range) duration of response (PR or better) was 9.3 (5.6-
not reached) months with Isa and 14.1 (11.3-19.2) months with
Isa-dex. Duration of response was similar when based on in-
vestigator assessment (Isa, 7.6 months; Isa-dex, 13.3 months).
PFS per IAC assessment was estimated based on 65 events
occurring in 59.6% of patients in the Isa arm and 31 events
occurring in 56.4% of patients in the Isa-dex arm. Median PFS
was 4.9 months (95% CI, 3.9-7.7) in the Isa arm and 10.2 months
(95% CI, 4.9-17.3) in the Isa-dex arm (hazard ratio [HR], 0.677;
95% CI, 0.440-1.043; P , .04) (Figure 3A). PFS was similar when
based on investigator assessment of response (Isa, 4.8 months;
Isa-dex, 7.6 months).
The median (range) duration of follow-up for OS was 12.9 (1-23)
months with Isa and 13.4 (1-24) months with Isa-dex. OS was
estimated based on 50 deaths (45.9% of patients) in the Isa arm
and 22 deaths (40.0% of patients) in the Isa-dex arm. Median OS
was 18.9 months (95% CI, 13.6-23.1) with Isa and 17.3 months
(95% CI, 15.4-not reached) with Isa-dex (HR, 0.799; 95% CI,
0.484-1.321; P 5 .19) (Figure 3B). OS at 12 months was 63.5%
(95% CI, 54.4-72.7) and 73.8% (62.0-85.6), with Isa and Isa-dex,
respectively.
In the Isa and Isa-dex arms, 72 (66.1%) of 109 patients and
26 (47.3%) of 55 patients went on to receive further anticancer
treatment, with a median time to next treatment of 5.8 months
(95% CI, 4.9-8.9) and 15.2 months (95% CI, 6.7-18.4), re-
spectively. These patients most commonly received regimens
containing dexamethasone (86.1% and 80.8%) followed by PIs
(58.3% and 61.5%), IMiDs (51.4% and 34.6%), alkylating agents
(37.5% and 46.2%), or daratumumab (19.4% and 11.5%) in the
Isa and Isa-dex arms.
Change in paraprotein
Of the patients with $1 postbaseline paraprotein assessment,
36 (37.1%) of 97 patients and 29 (58.0%) of 50 patients had a
$50% reduction in the Isa and Isa-dex arms, respectively
(Figure 4). Two patients in the Isa arm and 5 patients in the
Isa-dex arm achieved a 100% reduction in M-protein.
Safety
More than 91% of patients had $1 treatment-emergent AE
(TEAE). Any-grade TEAEs and grade 3 or higher TEAEs occurring







Isatuximab (20 mg/kg QW cycle 1, then Q2W)









Disease progression, 70 (64.2%)
Adverse event, 13 (11.9%)
Poor compliance to protocol, 1 (0.9%)
Withdrawn consent, 4 (3.7%)
Other reason, 8 (7.3%)
Discontinued, 40 (72.7%)
Disease progression, 33 (60.0%)
Adverse event, 5 (9.1%)
Poor compliance to protocol, 0
Withdrawn consent, 1 (1.8%)
Other reason, 1 (1.8%)
Figure 1. Study design and treatment disposition. Q2W, every 2 weeks; QW, once weekly. *At study cutoff January 21, 2019 (12 months after the last patient who enrolled
completed the first cycle of treatment).
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Table 1. Patient demographic data, disease characteristics, and treatment history (randomized population)
Variable Isatuximab monotherapy (n 5 109) Isatuximab 1 dexamethasone (n 5 55)
Age, median (range), y 68 (37–84) 66 (42–85)
$75 y 21 (19.3) 12 (21.8)
Female, n (%) 58 (53.2) 26 (47.3)
Race, n (%)
White 91 (83.5) 45 (81.8)
Black or African American 5 (4.6) 3 (5.5)
Asian 0 1 (1.8)
Other 13 (11.9) 6 (10.9)
Ethnicity, n (%)
Hispanic or Latino 19 (17.4) 9 (16.4)
Not Hispanic or Latino 90 (82.6) 46 (83.6)
Geographic region, n (%)
Europe 62 (56.9) 31 (56.4)
North America 23 (21.1) 10 (18.2)
Other 24 (22.0) 14 (25.5)
ECOG PS score (Karnofsky PS), n (%)
0 (100%) 48 (44.0) 27 (49.1)
1 (80–90%) 54 (49.5) 22 (40.0)
2 (60–70%) 7 (6.4) 6 (10.9)
Time since initial diagnosis, median (range), y 5.3 (0.7–21.1) 5.6 (1.2–23.0)
Type of myeloma at diagnosis, n (%)
Immunoglobulin A 20 (18.3) 12 (21.8)
Immunoglobulin G 45 (41.3) 29 (52.7)
Light chain (k and l) 33 (30.3) 10 (18.2)
Measurable paraprotein at baseline,* n (%)
Serum M-protein 75 (68.8) 40 (72.7)
Urine M-protein 12 (11.0) 10 (18.2)
k light chain 11 (10.1) 1 (1.8)
l light chain 10 (9.2) 3 (5.5)
ISS stage at baseline,† n (%)
I 27 (24.8) 15 (27.3)
II 37 (33.9) 20 (36.4)
III 45 (41.3) 20 (36.4)
Bone marrow plasma cells, median (range), % 23.5 (0.0-100) 29.0 (1.0-100)
Plasmacytoma at baseline,† n (%) 21 (19.3) 17 (30.9)
High-risk cytogenetics,†‡ n (%) 23 (21.1) 12 (21.8)
CrCl 15-60 mL/min/1.73 m2,§ n (%) 38 (34.9) 18 (32.7)
Prior lines of therapy, median (range) 4 (2-10) 4 (2-10)
Prior regimens, median (range) 5 (2-16) 5 (2-14)
CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; PS, performance status.
*One patient in each arm had data missing.
†Based on central laboratory data.
‡High-risk cytogenetics status, defined as presence of t(4;14) and/or del(17p), was unknown in 48 patients (29 patients in Isa arm and 19 patients in Isa-dex arm), based on central laboratory
data (n 5 100) and local laboratory data (n 5 16).
§Eight patients (4 in each arm) had CrCl 15 to 30 mL/min/1.73 m2.
ǁRefractory disease defined according to International Myeloma Working Group criteria.
¶Refractory to IMiD and PI.
#Refractory to lenalidomide, bortezomib, pomalidomide, and carfilzomib.
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presented in Table 2. Grade 3 or higher TEAEs considered to be
possibly drug-related occurred in 13.8% and 18.2% of patients in
the Isa and Isa-dex arms, respectively.
IRs and hematologic abnormalities were the most common
TEAEs (Table 2). IRs were reported in 44 (40.4%) of 109 patients
and 22 (40.0%) of 55 patients in the Isa and Isa-dex arms, re-
spectively. Most reactions were grade 1 or 2; five (4.6%) patients
in the Isa arm and two (3.6%) patients in the Isa-dex arm had a
grade 3 or higher IR. Overall, 6 (3.7%) of 164 patients dis-
continued the study due to IRs. Most IRs (98.6%) occurred with
the first infusion, and no IRs occurred from the third infusion onward.
There was a similar incidence of laboratory-measured grade 3 or
higher neutropenia (18.3% and 13.0%) and grade 3 or higher in-
fections (22.0% and 21.8%) in the Isa and Isa-dex arms, respectively.
The addition of dexamethasone increased the incidence of any-
grade TEAEs in the System Organ Class psychiatric disorders (from
11.9% to 30.9%, driven by insomnia [Isa, 1.8%; Isa-dex, 25.5%]), and
the System Organ Class gastrointestinal disorders (Table 2). The
gastrointestinal TEAEs most frequently reported in the Isa-dex arm
were diarrhea (11 patients [20.0%], nausea (8 patients [14.5%]), and
dyspepsia (4 patients [7.3%]); of these, only dyspepsia appeared
elevated compared with the Isa arm (2 patients [1.8%]), and there
was an accompanying decrease in vomiting and constipation.
Serious TEAEs occurred in 51 (46.8%) of 109 patients and 25 (45.5%)
of 55 patients in the Isa and Isa-dex arms, respectively. The most
commonly occurring serious TEAEs, which were predominantly
respiratory infections, disease progression, and infusion-related re-
actions, are presented in supplemental Table 1. These were con-
sidered possibly drug related in 14 (12.8%) of 109 patients in the Isa
arm and 6 (10.9%) of 55 patients in the Isa-dex arm.
Treatment was discontinued as a result of a TEAE in 13 (11.9%) of
109 patients in the Isa arm and 5 (9.1%) of 55 patients in the
Isa-dex arm. There were 19 fatal TEAEs (14 [12.8%] in the Isa
arm and 5 [9.1%] in the Isa-dex arm). Two deaths were considered
related to treatment with isatuximab (1 case of respiratory tract
infection and 1 case of sepsis); no deaths were considered related
to dexamethasone.
One of the 160 evaluable patients tested positive for anti-
isatuximab antibodies during the on-treatment period (Isa arm;
Table 1. (continued)
Variable Isatuximab monotherapy (n 5 109) Isatuximab 1 dexamethasone (n 5 55)
$1 prior stem cell transplant, n (%) 59 (54.1) 28 (50.9)
Refractory to an IMiD,ǁ n (%) 93 (85.3) 50 (90.9)
Refractory to lenalidomide 77 (70.6) 34 (61.8)
Refractory to pomalidomide 41 (37.6) 23 (41.8)
Refractory to a PI,ǁ n (%) 88 (80.7) 46 (83.6)
Refractory to bortezomib 71 (65.1) 37 (67.3)
Refractory to carfilzomib 30 (27.5) 11 (20.0)
Refractory to alkylating agent, n (%)ǁ 75 (68.8) 34 (61.8)
Double refractory, n (%)ǁ,¶ 76 (69.7) 42 (76.4)
Quadruple refractory, n (%)ǁ,# 7 (6.4) 4 (7.3)
Refractory to last regimen, n (%)ǁ 99 (90.8) 49 (89.1)
CrCl, creatinine clearance; ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; PS, performance status.
*One patient in each arm had data missing.
†Based on central laboratory data.
‡High-risk cytogenetics status, defined as presence of t(4;14) and/or del(17p), was unknown in 48 patients (29 patients in Isa arm and 19 patients in Isa-dex arm), based on central laboratory
data (n 5 100) and local laboratory data (n 5 16).
§Eight patients (4 in each arm) had CrCl 15 to 30 mL/min/1.73 m2.
ǁRefractory disease defined according to International Myeloma Working Group criteria.
¶Refractory to IMiD and PI.































Figure 2. Confirmed responses (safety population). Confirmed responses are
those assessed by IAC and defined according to International Myeloma Working
Group criteria for all treated patients. Serum immunofixation electrophoresis in-
terference has not been investigated and may underestimate depth of response.
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cycle 1 day 15) but was negative when next tested (cycle 2 day 1)
and remained so for the remainder of treatment (4 cycles started).
PK variables
At the dosing regimen used in this study (20 mg/kg once weekly
in cycle 1, then every 2 weeks), the estimated median (50th
percentile) and 90th percentile time to reach steady state was
43 days and 89 days, respectively, in the overall isatuximab PK
population. There was a 3.02 and 2.85 ratio in the geometric
mean of the trough concentration between cycle 2 day 1 and
cycle 1 day 8 in the Isa and Isa-dex arms, respectively. There was
a 1.68 and 1.92 ratio in the geometric means of the concen-
tration at the end of infusion between cycle 4 day 1 and cycle
1 day 1 in the Isa and Isa-dex arms, respectively. The PK analysis
showed that the addition of dexamethasone did not modify the
PK parameters of isatuximab.
Fc g receptor polymorphism
ORRs seemed similar between the FCGR3A F158V gene variants,
including those with high affinity for NK cell–immunoglobulin G
binding (V/V) and low binding affinity (V/F or F/F).18,19 In the Isa
group, the ORR was 22.2% (2 of 9) with V/V; 22.5% (9 of 40) with
F/F; and 24.1% (14 of 58) with F/V. In the Isa-dex group, the
ORR was 53.8% (7 of 13) with V/V; 42.9% (6 of 14) with F/F; and
40.0% (10 of 25) with F/F.
Immune monitoring and TCR repertoire
Peripheral blood immune monitoring showed an overall decrease
in total NK cells from cycle 1 day 1 to cycle 3 day 1 that was un-
affected by the addition of dexamethasone and was similar in re-
sponders andnonresponders (supplemental Figure 2A). However, a
detailed analysis of the NK cell compartment revealed a trend for
median values of the CD381 NK cells, particularly the CD381
CD561dim, CD161bright cytotoxic subset, to remain stable in
responding patients (supplemental Figure 2B-C). Although wemay
have expected the CD381 NK cells to be depleted by the anti-
CD38 regimen, as shown for daratumumab,20 this did not seem to
be the case among responders to isatuximab. The reasons for this
are unclear; however, wemay speculate that these cells continue to
contribute to the anti-myeloma response through ADCC.
CD31 T cells and the cytotoxic CD81 T-cell subsets showed a
modest increment from cycle 1 day 1 to cycle 3 day 1 in all patients
except responders to Isa-dex (supplemental Figure 2D-E),
whereas CD41 T cells remained stable (data not shown). A trend
for reduced median values of regulatory T cells was observed,
particularly in responders to Isa-dex (supplemental Figure 2F).
Isatuximab monotherapy induced expansion of clonotypic
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Figure 3. Survival outcomes according to treatment arm, per IAC as-
sessment (safety population). (A) PFS. (B) OS.
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cycle 1 to cycle 3 (24.4%; P , .0001) and cycle 5 (48.1%;
P , .0001) in peripheral blood, suggesting a T-cell immune
response. In the Isa-dex arm, there was a similar expansion of
clonotypic T cells from cycle 1 to cycle 3 (39.3%; P, .0001) and
cycle 5 (51.6%; P , .0001) (Figure 5), indicating that TCR
clonality was not modified by the addition of dexamethasone.
The addition of dexamethasone, with its increase in ORR, was not
associated with a further increase in TCR clonality. Also, the median
changes in T-cell clonality from baseline to cycle 3 day 1 among
responders were similar in both the Isa (31.8%) and Isa-dex (39.8%)
arms. However, higher depth of response seemed to be associated
with increased TCR clonality; median changes from baseline were
higher in patients achieving VGPR or better (Isa, 61.3%; Isa-dex,
61.5%) comparedwith PR (Isa, 23.8%; Isa-dex, 24.7%) andPRorworse
(Isa, 23.7%; Isa-dex, 23.5%) and was independent of treatment arm.
Discussion
In phase 2 stage 2 of this randomized phase 1/2 study in heavily
pretreated patients with RRMM, responses rates were clinically
significant with isatuximab 20mg/kg once weekly (cycle 1)/every
2 weeks as monotherapy (ORR of 23.9% by IAC, 27.5% by in-
vestigator assessment) and in combination with dexamethasone
(ORR of 43.6% by IAC, 45.5% by investigator assessment).
The study was not powered for comparison between treatment
arms. However, the addition of dexamethasone to isatuximab
monotherapy resulted in a significant increase in ORR (OR,
0.405; P5 .008) with improved depth of response and evidence
of increased PFS (HR, 0.677 [P, .04]; median PFS of 4.9months with
Isa and 10.2 months with Isa-dex). No patients in this study achieved
CR; however, the true CR rate may be underestimated because of
isatuximab interferencewithM-proteinmeasurement.21 TheHR for
OS favored Isa-dex compared with Isa but did not reach statistical
significance (HR, 0.799; P5 .19); after 12 months, 64% and 74% of
patients in the Isa and Isa-dex arms were still alive, respectively. OS
is affected by subsequent therapy, and there was a longer time to
next treatment in the Isa-dex arm, with more patients in the Isa arm
receiving subsequent IMiDs, PIs, and daratumumab than in the Isa-
dex arm. It was interesting to observe that median PFS with Isa-dex
in this study was longer (10.2 months) than that reported with
daratumumab monotherapy (3.7 months), although the difference
in 12 month OS was not as wide (74% vs 65%, respectively).
However, such direct comparisons must be interpreted with
caution, as we note that differences in participating countries
for our study (North and South America, Europe, Russia, and
Israel) compared with the SIRIUS (Daratumumab Monotherapy
in Patients With Treatment-Refractory Multiple Myeloma) study
(United States, Canada, and Spain) could have influenced the type
and availability of subsequent rescue therapies.
Isatuximab was generally well tolerated at a dosage of 20 mg/kg
once weekly (cycle 1)/every 2 weeks. As seen previously,14,22,23 IRs
were the most common TEAE, occurring in ;40% of patients in
both arms. All patients received infusion management prophylaxis,
and IRs were mostly mild to moderate in nature, with ,5% of
patients experiencinggrade3or higher IRs.Discontinuations due to
a TEAE were low, and thus the therapeutic potential of isatuximab
does not seem to be limited by its safety profile.
The addition of dexamethasone to isatuximab resulted in
moderate steroid-related toxicity that was manageable, did not
change the incidence of IRs or high-grade infections, and
resulted in a similar number of serious AEs and discontinuations
due to AEs or fatal AEs. There was no increase in hematologic
toxicity or infections with Isa-dex compared with Isa.
There were no meaningful differences in ORR with isatuximab in
patients with the NK cell high-affinity FCGR3A 158V/V variant
compared with patients with the low-affinity 158F/F or 158F/V
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Figure 4. Waterfall plot of best percent change in paraprotein
in individual patients (safety population).




 http://ashpublications.org/blood/article-pdf/137/9/1154/1801510/bloodbld2020008209.pdf by guest on 23 June 2021
Table 2. TEAEs and grade 3 or higher TEAEs (occurring in ‡5% of all patients by preferred term) and hematologic
abnormalities (safety population)
System organ class Isatuximab (n 5 109)
Isatuximab 1 dexamethasone
(n 5 55)
Preferred term All grades Grade 3 or higher All grades Grade 3 or higher
TEAEs, n (%) 100 (91.7) 53 (48.6) 51 (92.7) 33 (60.0)
Injury, poisoning, and procedural
complications
46 (42.2) 7 (6.4) 26 (47.3) 3 (5.5)
IRs* 44 (40.4) 5 (4.6) 22 (40.0) 2 (3.6)
Infections and infestations 65 (59.6) 24 (22.0) 33 (60.0) 12 (21.8)
URTI 14 (12.8) 1 (0.9) 8 (14.5) 1 (1.8)
Pneumonia 10 (9.2) 7 (6.4) 6 (10.9) 3 (5.5)
Bronchitis 7 (6.4) 1 (0.9) 4 (7.3) 3 (5.5)
Nasopharyngitis 4 (3.7) 0 7 (12.7) 0
Respiratory tract infection 5 (4.6) 3 (2.8) 4 (7.3) 1 (1.8)
Urinary tract infection 8 (7.3) 1 (0.9) 1 (1.8) 0
Respiratory, thoracic, and mediastinal
disorders
50 (45.9) 11 (10.1) 23 (41.8) 2 (3.6)
Cough 19 (17.4) 0 9 (16.4) 0
Dyspnea 19 (17.4) 2 (1.8) 8 (14.5) 0
Nasal congestion 9 (8.3) 0 2 (3.6) 0
Metabolism and nutrition disorders 20 (18.3) 3 (2.8) 7 (12.7) 0
Decreased appetite 12 (11.0) 1 (0.9) 4 (7.3) 0
Psychiatric disorders 13 (11.9) 0 17 (30.9) 3 (5.5)
Insomnia 2 (1.8) 0 14 (25.5) 1 (1.8)
Nervous system disorders 37 (33.9) 7 (6.4) 21 (38.2) 5 (9.1)
Headache 14 (12.8) 0 8 (14.5) 0
Gastrointestinal disorders 41 (37.6) 3 (2.8) 27 (49.1) 4 (7.3)
Diarrhea 21 (19.3) 0 11 (20.0) 2 (3.6)
Nausea 16 (14.7) 1 (0.9) 8 (14.5) 0
Vomiting 14 (12.8) 1 (0.9) 3 (5.5) 0
Constipation 10 (9.2) 1 (0.9) 3 (5.5) 0
Dyspepsia 2 (1.8) 0 4 (7.3) 0
Musculoskeletal and connective tissue
disorders
58 (53.2) 7 (6.4) 27 (49.1) 4 (7.3)
Back pain 22 (20.2) 2 (1.8) 9 (16.4) 0
Pain in extremity 9 (8.3) 1 (0.9) 9 (16.4) 2 (3.6)
Arthralgia 9 (8.3) 0 4 (7.3) 0
Musculoskeletal chest pain 9 (8.3) 0 4 (7.3) 0
Bone pain 10 (9.2) 0 1 (1.8) 0
Myalgia 8 (7.3) 0 3 (5.5) 1 (1.8)
Musculoskeletal pain 7 (6.4) 2 (1.8) 3 (5.5) 0
General disorders and administration site
conditions
45 (41.3) 11 (10.1) 26 (47.3) 4 (7.3)
Fatigue 19 (17.4) 3 (2.8) 10 (18.2) 0
Asthenia 8 (7.3) 1 (0.9) 6 (10.9) 1 (1.8)
Chills 9 (8.3) 0 5 (9.1) 0
Pyrexia 5 (4.6) 0 7 (12.7) 1 (1.8)
Peripheral edema 5 (4.6) 0 5 (9.1) 0
Disease progression 7 (6.4) 7 (6.4) 2 (3.6) 2 (3.6)
Pain 6 (5.5) 1 (0.9) 3 (5.5) 0
Hematologic abnormalities, n/N (%)†
Anemia 104/109 (95.4) 25/109 (22.9) 52/54 (96.3) 8/54 (14.8)
Platelet count decreased 73/109 (67.0) 20/109 (18.3) 32/54 (59.3) 8/54 (14.8)
Neutrophil count decreased 72/109 (66.1) 20/109 (18.3) 20/54 (37.0) 7/54 (13.0)
Lymphocyte count decreased 91/109 (83.5) 30/109 (27.5) 47/54 (87.0) 26/54 (48.1)
URTI, upper respiratory tract infection.
*IRs of grade 3 or higher were prespecified as an AE of special interest.
†Based on laboratory values measured during the on-treatment period.
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Immune monitoring of regulatory T-cell and NK cell populations
showed similar kinetics with both Isa and Isa-dex, and confirmed
that dexamethasone had no detrimental effect in the number of
CD81 cytotoxic T cells. Interestingly, there was a lower decrease
in the cytotoxic subset of NKCD381 cells in responders compared
with nonresponders. Abnormal T-cell function is associated with
immunosenescence in the MM tumor microenvironment.24 In-
duction of clonal T-cell expansion has previously been observed as
part of the immunomodulatory action of anti-CD38 antibodies.25
We confirm that T-cell clonal expansion also occurs with isatuximab
treatment, suggesting progress toward reconstitution of T-cell
adaptive immunity. This seems to coincide with an immune re-
sponse to myeloma-associated antigens (including CD38) in pa-
tients treatedwith isatuximabmonotherapy.26 TCR clonality was not
further modified by the addition of dexamethasone, despite
a known inhibitory effect of corticosteroids on naive T-cell
differentiation.27 Thus, the increased response rate in the Isa-dex
arm did not seem to be associated with increased T-cell clonality;
however, T-cell clonality did seem greater among patients with
deeper responses (VGPR or better vs PR or worse) when measured
on day 1 of cycle 3.
The ORR of 44% with Isa-dex in this study compares favor-
ably to the clinical response rate observed for pomalidomide
plus dexamethasone (33% ORR),28 carfilzomib plus dexa-
methasone (55%),29 selinexor plus dexamethasone (22%), and
the novel alkylating agent melflufen plus dexamethasone
(40%)30 in other populations of heavily pretreated patients
with RRMM. Clinical trials of daratumumab monotherapy in pa-
tients with RRMM, which included corticosteroids as part of the
premedication and postmedication IR prophylaxis, observed
ORRs in the range of 29% to 36%.31,32 Uniquely, in the Isa-dex arm,
there was a median PFS benefit of 10.2 months, which is longer
than has been shown with IMiDs33 or with daratumumab mono-
therapy (median PFS range, 3.7-5.6 months).31,32
The efficacy and safety of isatuximab 10mg/kg in combination with
pomalidomide plus dexamethasone for the treatment of RRMM
were confirmed in the phase 3 ICARIA-MM (Isatuximab 10 mg/kg
QW/Q2W in Combination with pomalidomide And low-dose
dexamethasone veRsus pomalidomide and low-dose dexametha-
sone In patients with relapsed And refractory Multiple Myeloma)
study (#NCT02990338).34 In ICARIA-MM, PFS was significantly
improved with isatuximab in combination with pomalidomide plus
dexamethasone vs pomalidomide and dexamethasone (median,
11.53 vs 6.47 months; HR, 0.596; 95% CI, 0.436-0.814; P 5 .001).
Despite 2 patients in the Isa arm and 5 patients in the Isa-dex arm
achieving a100% reduction inM-protein, therewere noCRs recorded.
However, interference of therapeutic antibodies with immunofixation
and serum protein electrophoresis assays used in response assess-
ments may therefore lead to underestimation of CR and VGPR.35
The addition of dexamethasone to isatuximab resulted in a
clear increase in response, depth of response, and a trend to-
ward improved long-term outcomes with no detrimental effect
on safety. This study provides the rationale for including dexa-
methasone in effective combination regimens with isatuximab.
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Figure 5. TCR clonality with successive treatment cycles. C, cycle; D, day.
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